Clinical Trials Sponsored by ArmaGen, Inc

Total 36987 results

Amgen

Completed

Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Relapsed Multiple Myeloma

United States, Canada
Amgen

Withdrawn

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

United States
Amgen

Completed

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease

End-stage Renal Disease | Relapsed Multiple Myeloma

United States, Australia, Canada
Amgen

Completed

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Multiple Myeloma | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia | Hodgkin's Disease

United States
Amgen

Completed

Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab

Relapsed or Plateau-Phase Multiple Myeloma
Amgen

Completed

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Romania, Canada, Korea, Republic of, Philippines, Lithuania, Serbia, Latvia, Estonia, Greece, India, China, Croatia, Mexico, Malaysia, Chile, Brazil
Amgen

Terminated

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Austria, Belgium, Italy, Netherlands, Spain, Canada, Denmark, Germany, Korea, Republic of, Russian Federation, Hong Kong, Greece, Japan
Amgen

Completed

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Lupus Arthritis, Systemic Lupus Erythematosus

United States, Taiwan, Germany, Denmark, Australia, United Kingdom, Malaysia, France
Amgen

Completed

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

United States, France, Italy, Spain, United Kingdom, Belgium, Canada, Poland, Switzerland, Korea, Republic of, Russian Federation, Hong Kong, Portugal, South Africa, Israel, Romania, Bulgaria, Greece, Australia, Sweden, Japan, Latvia and more
Amgen

Completed

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

Asthma

United States
Amgen

Completed

Long-Term Assessment of Safety and Physical Function With AMG 108 in RA

Rheumatoid Arthritis
Amgen

Terminated

Study of South African Dialysis Patients

Chronic Kidney Disease, Receiving Dialysis

South Africa
Amgen

Completed

Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection

Healthy Men and Women
Amgen

Completed

AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Asthma
Amgen

No longer available

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Unresected Stage IIIb to IVM1c Melanoma

United States
Amgen

Completed

Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ

Part 1- Advanced Solid Tumors | Part 2- Advanced or Metastatic Gastric Cancer | Part 2- Advanced or Metastatic GEJ

Japan
Amgen

Completed

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Renal Impairment

United States
Amgen

Completed

Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients

Locally Recurrent and Metastatic Breast Cancer

United States, United Kingdom, Denmark, Poland, Belgium, Hungary, Spain, Austria, France, Australia, Netherlands, Finland, India
Amgen

Terminated

An Open Label Treatment Extension Study of AMG 706

Solid Tumors
Amgen

Completed

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Carcinoma | Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumors | Oncology | Tumors | Metastases | Gynecological Malignancies

Belgium, United States, Australia
Amgen

Completed

A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma

Carcinoma | Cancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Gastrointestinal Cancer | Oncology | Metastases
Amgen

Withdrawn

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada
Amgen

Completed

Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

Sarcoma | Soft Tissue Sarcoma | Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma
Amgen

Completed

A Phase II Study to Treat Advanced Malignant Glioma

Advanced Malignant Glioma
Amgen

Completed

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Terminated

Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects

Migraine

United States
Amgen

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States, United Kingdom
Amgen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Crohn's Disease | Ulcerative Colitis

United States, Australia
Amgen

Completed

Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer

Castrate-resistant Prostate Cancer

United Kingdom, Czech Republic
Amgen

Completed

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States
Amgen

Completed

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Migraine

United States
Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Amgen

Completed

Moderate to Severe Plaque Psoriasis With Scalp Involvement

Psoriasis
Amgen

Completed

Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease (BONAFIDE)

Secondary Hyperparathyroidism

United States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
Amgen

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer

Colon Cancer
Amgen

Completed

AMG 151 Amgen Protocol Number 20100761

Diabetes Mellitus

United States, Puerto Rico, Poland, Estonia, Czech Republic
Amgen

Completed

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Lymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
Amgen

Completed

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

United Kingdom, Czech Republic
Amgen

Completed

Study to Evaluate the Prospective Payment System (STEPPS™)

Chronic Kidney Disease

United States, Puerto Rico
Amgen

Terminated

Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus | Lupus

United States, Australia, Canada
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
Amgen

Completed

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Gastric Cancer | Esophageal Cancer | Esophagogastric Junction Adenocarcinoma
Amgen

Completed

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic Purpura
Amgen

Withdrawn

Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With Asthma

Asthma
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Psoriasis

United States
Amgen

Completed

A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density

Osteoporosis | Osteopenia | Low Bone Mineral Density
Amgen

Completed

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

Thyroid Cancer
Amgen

Completed

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral Density
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Amgen

Completed

Study to Assess Darbepoetin Alfa in Subjects With Chronic Kidney Disease

Chronic Kidney Disease | Kidney Disease

3

Subscribe